Get the Stockscreener App
47.37
0.34%
-0.16
After Hours:
47.37
Gsk Plc Adr stock is traded at $47.37, with a volume of 4.63M.
It is down -0.34% in the last 24 hours and up +7.88% over the past month.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
See More
Previous Close:
$47.53
Open:
$47.03
24h Volume:
4.63M
Relative Volume:
0.92
Market Cap:
$95.48B
Revenue:
$42.06B
Net Income/Loss:
$7.96B
P/E Ratio:
13.51
EPS:
3.5062
Net Cash Flow:
$5.64B
1W Performance:
-2.15%
1M Performance:
+7.88%
6M Performance:
+25.85%
1Y Performance:
+40.61%
1-Day Range:
$46.96
$47.48
1-Week Range:
$46.96
$48.69
52-Week Range:
$31.71
$48.69
Gsk Plc Adr Stock (GSK) Company Profile
Name
Gsk Plc Adr
Sector
Industry
Phone
-
Address
-
Compare GSK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
47.37 | 95.48B | 42.06B | 7.96B | 5.64B | 3.5062 |
|
LLY
Lilly Eli Co
|
1,030.05 | 914.44B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
200.00 | 480.85B | 92.15B | 25.12B | 20.46B | 10.36 |
|
AMGN
Amgen Inc
|
343.99 | 184.00B | 35.89B | 7.01B | 11.54B | 12.94 |
|
ABBV
Abbvie Inc
|
233.87 | 413.57B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
96.43 | 230.48B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-25 | Downgrade | Berenberg | Buy → Hold |
| Apr-15-25 | Initiated | Exane BNP Paribas | Neutral |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-15-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Nov-12-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-24 | Downgrade | UBS | Buy → Neutral |
| May-30-24 | Initiated | Goldman | Neutral |
| Mar-04-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-13-24 | Upgrade | Citigroup | Neutral → Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Jan-03-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Mar-17-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-27-23 | Resumed | Goldman | Buy |
| Jan-03-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-11-22 | Downgrade | UBS | Neutral → Sell |
| Sep-15-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Sep-08-22 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-21-22 | Resumed | Citigroup | Neutral |
| Feb-11-22 | Downgrade | DZ Bank | Buy → Hold |
| Nov-05-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Jun-24-21 | Upgrade | Deutsche Bank | Sell → Hold |
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-04-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-20-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jan-15-21 | Initiated | Deutsche Bank | Hold |
| Nov-02-20 | Upgrade | Liberum | Hold → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Feb-12-20 | Downgrade | Shore Capital | Hold → Sell |
| Jan-16-20 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-19 | Initiated | SVB Leerink | Outperform |
| Nov-21-19 | Upgrade | UBS | Neutral → Buy |
| Oct-11-19 | Upgrade | Cantor Fitzgerald | Hold → Buy |
| Sep-03-19 | Resumed | Citigroup | Neutral |
| Sep-03-19 | Upgrade | Societe Generale | Sell → Buy |
| Aug-13-19 | Resumed | JP Morgan | Neutral |
| Jun-17-19 | Resumed | Morgan Stanley | Underweight |
| Mar-08-19 | Downgrade | Shore Capital | Buy → Hold |
| Feb-22-19 | Downgrade | UBS | Buy → Neutral |
| Jan-14-19 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Aug-30-18 | Downgrade | Liberum | Buy → Hold |
| Apr-04-18 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-22-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-09-18 | Upgrade | Kepler | Reduce → Hold |
View All
Gsk Plc Adr Stock (GSK) Latest News
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
GSK PLC Share Price: What to Know Before the London Market Opens on 17 November 2025 - ts2.tech
The Best Healthcare Stock to Hold in Uncertain Times - Finviz
IMU Biosciences announces formation of Scientific Advisory Board - GlobeNewswire Inc.
Looking Into GSK PLC's Recent Short Interest - Sahm
3 Dividend Stocks for November 2025 - Morningstar
10 Best Value Stocks to Buy for the Long Term - Morningstar
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Analysts - MarketBeat
Arkadios Wealth Advisors Acquires 6,734 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR Plans Quarterly Dividend of $0.42 (NYSE:GSK) - MarketBeat
GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology - Morningstar
GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View - TradingView
GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026 - Sahm
Here's Why GSK (GSK) is a Strong Growth Stock - Yahoo Finance
ETFs Investing in GSK plc Sponsored ADR Stocks - TradingView
Whittier Trust Co. Sells 5,805 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK plc Sponsored ADR (GSK) Stock Forecast & Price Targets: Today, Tomorrow, Next Week - Traders Union
GSK plc Sponsored ADR (GSK) Stock Price Prediction for 2025, 2026, 2030-2040 - Traders Union
FDA Approves GSK's Withdrawn Blood Cancer Drug Blenrep - Sahm
J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK) - The Globe and Mail
GSK PLC Sponsored ADR $GSK Shares Acquired by Ethic Inc. - MarketBeat
Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce - Sahm
Stanley Laman Group Ltd. Decreases Stock Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment - Sahm
The Best Healthcare Stocks to Buy - Morningstar
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential - Sahm
Rep. Val T. Hoyle Sells GSK PLC Sponsored ADR (NYSE:GSK) Stock - MarketBeat
GSK PLC Sponsored ADR (NYSE:GSK) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy - The Globe and Mail
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Why GSK (GSK) is a Top Value Stock for the Long-Term - sharewise.com
GSK PLC (GSK) Stock Price, Trades & News - GuruFocus
AnaptysBio Charts Path To Split Into Two Public Companies By 2026 - Sahm
Park Place Capital Corp Raises Stock Position in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Bought by Farther Finance Advisors LLC - Defense World
GlaxoSmithKline (GSK) Gets a Hold from Barclays - The Globe and Mail
Sound Income Strategies LLC Has $16.56 Million Position in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Sold by Clean Yield Group - MarketBeat
The 10 Best Companies to Invest in Now - Morningstar
Amgen Expands US Manufacturing Network Amid New Tariff Policy - Sahm
TD Private Client Wealth LLC Raises Stock Position in GSK PLC Sponsored ADR $GSK - MarketBeat
Pneumococcal Vaccine Market Opportunities and Strategies to 2034 - GlobeNewswire Inc.
Miller Howard Investments Inc. NY Purchases 13,023 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock? - The Globe and Mail
Gsk Plc Adr Stock (GSK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):